Phillip Unsworth
About Phillip Unsworth
Phillip Unsworth is a Senior Drug Discoverer at BenevolentAI in Cambridge, United Kingdom, with over 5 years of experience in drug discovery and a strong background in Chemistry.
Company
Phillip Unsworth is currently working at BenevolentAI, a company situated in Cambridge, United Kingdom. BenevolentAI is noted for its efforts in leveraging artificial intelligence technologies to accelerate drug discovery and development processes. Phillip has been a part of the company since April 2018, contributing to their mission with his extensive background in chemistry and drug discovery.
Title
Phillip Unsworth holds the title of Senior Drug Discoverer at BenevolentAI. His role involves working on innovative projects aimed at discovering new drugs and improving existing treatments. His position reflects his expertise and long-term commitment to the field of drug discovery.
Education and Expertise
Phillip Unsworth has a strong academic background in chemistry. He earned his Doctor of Philosophy (PhD) in Chemistry from the University of Bristol, a program he attended from 2010 to 2014. Additionally, he holds an MCHEM in Chemistry from the University of Oxford, which he also completed from 2010 to 2014. His educational accomplishments provide the foundation for his expertise in drug discovery and research.
Professional Background
Phillip Unsworth's professional journey includes several key roles. He was a Senior Scientist at Proximagen in Babraham, Cambridge, from 2016 to 2018, where he worked on drug discovery projects. Prior to that, he served as a Postdoctoral Research Fellow at Queen's University in Kingston, Ontario, from 2015 to 2016. His diverse experiences across different institutions significantly contribute to his proficiency in the field.
Drug Discovery Experience
With over five years of experience in drug discovery, Phillip Unsworth has developed substantial expertise in this domain. At Proximagen, he engaged in various drug discovery projects that aimed at developing new therapeutic solutions. His current role at BenevolentAI enables him to apply his deep knowledge and skills in the development of innovative drugs, supported by advanced AI technology.